DANZITEN (Nilotinib Tartrate) Patent Expiration, LOE Window & CMS Spending

DANZITEN (Nilotinib Tartrate) by Azurity: FDA Orange Book core substance LOE 2040-02-18, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $18,025 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN219293 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-02-18
Last Listed Patent or Exclusivity Date2040-02-18
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($18,025 intro WAC)